Granite Investment Partners LLC Sells 30,016 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Granite Investment Partners LLC lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 409,281 shares of the biopharmaceutical company’s stock after selling 30,016 shares during the quarter. Granite Investment Partners LLC owned about 0.32% of Halozyme Therapeutics worth $19,568,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of HALO. HighTower Advisors LLC grew its position in shares of Halozyme Therapeutics by 20.2% in the third quarter. HighTower Advisors LLC now owns 36,174 shares of the biopharmaceutical company’s stock valued at $2,080,000 after purchasing an additional 6,075 shares in the last quarter. Stifel Financial Corp grew its holdings in Halozyme Therapeutics by 126.3% during the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 9,555 shares in the last quarter. MML Investors Services LLC increased its position in shares of Halozyme Therapeutics by 80.7% during the third quarter. MML Investors Services LLC now owns 9,779 shares of the biopharmaceutical company’s stock valued at $560,000 after buying an additional 4,366 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Halozyme Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after buying an additional 30,901 shares in the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in shares of Halozyme Therapeutics by 34.7% in the third quarter. Coldstream Capital Management Inc. now owns 9,251 shares of the biopharmaceutical company’s stock valued at $534,000 after acquiring an additional 2,384 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on HALO shares. Benchmark reaffirmed a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,200 shares of company stock worth $1,286,568 in the last 90 days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $60.22 on Friday. The business’s 50-day moving average price is $60.22 and its 200-day moving average price is $54.93. The firm has a market capitalization of $7.44 billion, a PE ratio of 17.56, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.